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Abstract
Background: We previously identified brain type fatty acid-binding protein (FABP7) as a prognostic marker for patients with
glioblastoma (GBM). Increased expression of FABP7 is associated with reduced survival. To investigate possible molecular
mechanisms underlying this association, we compared the expression and subcellular localization of FABP7 in non-tumor brain
tissues with different types of glioma, and examined the expression of FABP7 and epidermal growth factor receptor (EGFR) in
GBM tumors.
Methods: Expression of FABP7 in non-tumor brain and glioma specimens was examined using immunohistochemistry, and its
correlation to the clinical behavior of the tumors was analyzed. We also analyzed the association between FABP7 and EGFR
expression in different sets of GBM specimens using published DNA microarray datasets and semi-quantitative
immunohistochemistry. In vitro migration was examined using SF763 glioma cell line.
Results: FABP7 was present in a unique population of glia in normal human brain, and its expression was increased in a subset
of reactive astrocytes. FABP7 immunoreactivity in grade I pilocytic astrocytoma was predominantly cytoplasmic, whereas
nuclear FABP7 was detected in other types of infiltrative glioma. Nuclear, not cytoplasmic, FABP7 immunoreactivity was
associated with EGFR overexpression in GBM (N = 61, p = 0.008). Expression of the FABP7 gene in GBM also correlated with
the abundance of EGFR mRNA in our previous microarray analyses (N = 34, p = 0.016) and an independent public microarray
dataset (N = 28, p = 0.03). Compared to those negative for both markers, nuclear FABP7-positive/EGFR-positive and nuclear
FABP7-positive/EGFR-negative GBM tumors demonstrated shortest survival, whereas those only positive for EGFR had
intermediate survival. EGFR activation increased nuclear FABP7 immunoreactivity in a glioma cell line in vitro, and inhibition of
FABP7 expression suppressed EGF-induced glioma-cell migration. Our data suggested that in EGFR-positive GBM the presence
of nuclear FABP7 immunoreactivity increases the risk of poor prognosis
Conclusion: In this study, we identified a possible mechanism as the basis of the association between nuclear FABP7 and poor
prognosis of GBM. FABP7 expression can be found in all grades of astrocytoma, but neoplastic cells with nuclear FABP7 were
only seen in infiltrative types of tumors. Nuclear FABP7 may be induced by EGFR activation to promote migration of GBM tumor
cells. Positive nuclear FABP7 and EGFR overexpression correlated with short survival in EGFR-positive GBM patients.
Therefore, nuclear FABP7 immunoreactivity could be used to monitor the progression of EGFR-overexpressed GBM.
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Background
GBM is the highest grade of astrocytoma and is also the
most common primary brain tumor in adults. Approxi-
mately 50% of patients with GBM die within a year of
diagnosis, despite the use of many aggressive treatment
approaches [1]. Lack of reliable prognostic markers for
these patients is a hindrance to improving therapy and
individualizing therapeutic interventions. Amplification
and/or overexpression of the EGFR gene, mutation of the
p53  gene, and proliferation indices have all been pro-
posed to predict survival of patients with GBM and to play
a role in the pathophysiology of their tumors [2,3]; how-
ever, other studies have shown no such association with
outcome [4-6]. One reason for this discrepancy is that
strong clinical factors such as patient age need to be
included [7,8]. Although clinical parameters such as age,
Karnofsky performance status at diagnosis, and extent of
resection are routinely used in clinical practice to predict
the outcome of patients with GBM, none of these varia-
bles have a direct connection with tumor pathogenesis.
In a previous study, gene expression profiling of a group
of GBM specimens identified a cluster of about 50 named
genes whose expression was inversely associated with sur-
vival [9]. In examining the annotations of "biological
process" in the Gene Ontology terms for each gene [10],
the annotation "neurogenesis" appeared most frequently,
suggesting a common role for these genes in central nerv-
ous system development. In contrast, a number of other
annotations for biological process such as "cell prolifera-
tion," "inflammatory response," and "immune response"
were underrepresented in these genes. Because several of
these genes are involved in cell-cell and cell-matrix inter-
actions and cell migration, we hypothesized that their
increased expression might be related to more infiltrative
and aggressive tumor behavior. Based on the results of the
preceding analyses and the availability of antibodies, we
chose to investigate the prognostic value of one gene,
FABP7, in greater detail [9].
Although FABP7 is a cytoplasmic protein, its varying sub-
cellular localization between nucleus and cytoplasm has
been reported in developing brain [11], glioma cell lines
[12], and GBM specimens [9]. Increased FABP7 expres-
sion was also found in glia following nerve injury [13,14].
We separately scored FABP7 immunoreactivity in nucleus
and cytoplasm, and found that nuclear FABP7 immunore-
activity was inversely correlated with survival of patients
with GBM, particularly in younger cases [9]. This result is
consistent with other reports that emphasize the effect of
age upon various prognostic factors [7,8], and such a pat-
tern is similar to a recent finding of an association
between EGFR overexpression and poor prognosis in
younger GBM patients [7].
FABP7 is a member of the multi-gene fatty acid-binding
protein (FABP) family and binds to very-long-chain poly-
unsaturated fatty acids (C > 16) such as docosahexaenoic
acid (DHA) with very high affinity in vitro [15]. FABP7
appears to have different roles in different tissue types. It
is highly expressed in radial and Bergmann glial cells
throughout the developing central nervous system and
gradually declines in the adult [16,17]. FABP7 is required
for neuron-induced glial differentiation and subsequent
migration of neurons along the glial processes, but has no
effect on cell proliferation and adhesion [11]. In Schwann
cells, FABP7 expression is downstream of the Ras-inde-
pendent EGFR signaling pathway, and it regulates interac-
tions between Schwann cells and axons in normal
peripheral nerves and peripheral nerve tumors without
affecting cell proliferation and migration [13]. Differen-
tial expression of different types of FABPs is found in sev-
eral types of tumors and their normal-cell counterparts,
and FABPs have been shown to modulate growth and dif-
ferentiation of normal and neoplastic cells [18]. FABP7
was also shown to induce mammary differentiation and
to mediate growth inhibition of breast cancer cells
[19,20].
It has been suggested that FABPs increase the solubility of
fatty acids in the cytoplasm when transporting fatty acids
between membrane compartments, and bring fatty acids
to their nuclear targets [21]. In addition, subcellular local-
ization of FABPs appears to be tissue specific and closely
associated with gene expression and function. Liver-type
FABP targets fatty acids to the nucleus and interacts with
peroxisome proliferator-activated receptors α and γ to reg-
ulate gene expression [22-24]. Soluble FABP7 was found
to induce differentiation of the mammary gland in mice
[20]. FABP7 is present in both the nucleus and cytoplasm
in glial cells, as well as in the conditioned media of glial
cells in culture [11], but is found only in the cytoplasm of
Kupffer cells in the liver [25].
In this study, we examined the expression patterns and
subcellular localization of FABP7 in specimens from nor-
mal individuals, from individuals with gliosis only, and
from patients with gliomas differing in grade and histol-
ogy. We also used independent sets of GBM specimens to
analyze the relationship of subcellular localization of
FABP7 with patient outcome and EGFR expression, and to
seek possible mechanisms underlying the functions of
FABP7 in GBM.
Methods
Cell culture
Glioma cell lines were obtained from the Neurosurgery
Tissue Bank at the University of California, San Francisco.
Immortalized human astrocytes were provided by Dr.
Russ Pieper (University of California, San Francisco) [26].BMC Cancer 2006, 6:97 http://www.biomedcentral.com/1471-2407/6/97
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All cells were maintained in Eagle's minimal essential
medium with 10% FBS and 5% CO2.
Tissue specimens
Frozen and paraffin-embedded specimens were obtained
from the Neurosurgery Tissue Bank at the University of
California, San Francisco, and University of Texas, M. D.
Anderson Cancer Center after approval from the Commit-
tee on Human Research. Tissue sections for immunohis-
tochemistry were of 5 µm in thickness. Gliotic and normal
brain tissues were obtained from epileptic patients and
postmortem specimens, respectively. Clinical data of
patients with primary GBM that were used for analyzing
the correlation between FABP7 and EGFR immunoreactiv-
ity are summarized in Tables 2 and 4. Two cohorts of GBM
patients (61 and 44 cases, respectively) for EGFR expres-
sion analysis are the same sets used in a previous study
[9].
Antibodies
FABP7-specific polyclonal antibodies were gifts from Drs.
N. Heintz (Rockefeller University, New York, NY) and R.
Godbout (University of Alberta, Alberta, Canada). Anti-
bodies from both sources produced similar staining pat-
terns and specificity on Western blots and
immunohistochemistry using GBM specimens ([12] and
data not shown). A dilution of 1 to 400 was used for both
immunostaining and migration assays, and a dilution of
1 to 500 was used for immunoblotting; secondary anti-
bodies alone did not show detectable signal. Dilution of
antibodies against glial fibrillary acidic protein (GFAP)
(ICN; Costa Mesa, CA) and EGFR (clone F4; Sigma, St.
Louis, MO) for immunohistochemistry was 1:1000 and
1:400, respectively. Peroxidase-conjugated and bioti-
nylated secondary antibodies were obtained from Vector
Laboratories (Burlingame, CA). Fluorescine-conjugated
and Rhodamine-conjugated secondary antibodies and
normal rabbit serum were obtained from Jackson Immu-
noResearch Laboratories (West Grove, PA).
Western blot analysis
Total RNA was extracted from frozen tissues specimens
using Trizol (Invitrogen; Carlsbad, CA) as described previ-
ously [9], and genomic DNA was removed from the inter-
phase and organic phase by ethanol precipitation. The
protein fraction was then purified by isopropanol precip-
itation, washed several times in 0.3 M guanidine hydro-
chloride in 95% ethanol, and resuspended in 1% SDS.
The protein concentration of each sample was quantitated
by using a Dc Protein Assay Kit (Bio-Rad; Hercules, CA),
and equal amounts of protein for each sample were sepa-
rated by SDS-PAGE and transferred to nitrocellulose
membranes (Bio-Rad), blocked with 10% skim milk,
incubated with specific antibodies, and visualized using a
Super Signal West Pico Chemiluminescent kit (Pierce;
Rockford, IL).
Immunohistochemistry
All frozen tissue sections used for immunohistochemistry
were fixed in 4% formaldehyde, treated with H2O2,
blocked with normal serum, incubated with primary anti-
bodies at 4°C overnight or room temperature (RT) 2
hours, incubated with biotinylated secondary antibody
and peroxidase-labeled streptavidin at RT for 30 min, to
visualize the immunoreactivity with the DAB Reagent kit
(KPL; Gaithersburg, MA). Staining of paraffin-embedded
sections followed the same protocol, except for prior de-
waxing and antigen retrieval by microwave heating.
Immunostaining and semi-quantitative scoring of p53
and EGFR expression were performed as previously
described [7].
SF763 glioma cells were plated and incubated overnight
in Lab-Tek chamber slides (Nalge Nunc International;
Rochester, NY) followed by 24 hours of 0.5% serum star-
vation and 2 days of 50 ng/ml EGF (Invitrogen) treat-
ment. After fixation in 4% formaldehyde, cells were
blocked with normal serum, followed by 2 hours of RT
incubation with the primary antibody and 1 hour of RT
incubation with the secondary antibody. Cells were then
covered with Vectashield (Vector Laboratories) to prevent
fading of fluorescence. The fluorescence intensity of 200
control or EGF-treated cells was digitally recorded and the
ratios were calculated.
Antisense inhibition and migration assay
Antisense oligodeoxynucleotides (ODNs) used were com-
plementary to the position -13 to 7 of the FABP7 cDNA,
and sense ODNs complementary to the same region were
used as a control. The first 3 and the last 3 phosphodiester
bonds on the ODNs were modified to phosphorothioate
bonds to prevent degradation. SF763 glioma cells were
serum-starved in 0.5% serum-containing medium for 24
hours, followed by 2 days of 50 ng/ml EGF treatment in
the same low-serum media. Control cells were main-
tained in the low-serum medium for 2 days. ODNs were
incubated with FuGene (Roche, Basel, Switzerland) at RT
for 30 min, and then added to SF763 cells on the second
day of EGF treatment to a final concentration of 100 nM.
The inserts of TransWell chambers (Corning, Corning,
NY) with 5µm pores were incubated with 100 µg/ml of
rat-tail type 1 collagen (BD Biosciences, San Jose, CA)
overnight at room temperature, and washed with phos-
phate-buffered saline (PBS). At the end of the 2-day EGF
treatment, cells were dislodged using 2 mM EDTA in PBS
and then resuspended in the same treatment media as
before (control or EGF, sense or antisense ODNs). Low-
serum medium was placed in the bottom well, and 1 × 104BMC Cancer 2006, 6:97 http://www.biomedcentral.com/1471-2407/6/97
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Several groups of glial cells in adult normal and gliotic brains expressed FABP7 Figure 1
Several groups of glial cells in adult normal and gliotic brains expressed FABP7. A, scattered FABP7-positive Type 1 cells 
(arrowheads) were detected in normal cerebral cortex. Nuclei of these cells were irregular or elongated, and appeared to be 
larger than those of oligodendrocytes. B, FABP7-positive Type 1 cells usually had only one or two processes (arrowheads), and 
were distinctive from GFAP-expressing astrocytes bearing elaborate processes (arrow). C and D, all FABP7-positive Type 2 
cells localized at the subpial layer had numerous processes and expressed GFAP. Arrowheads in C indicate pia. Some GFAP+/
FABP7- astrocytes could be seen. E, scattered FABP7-positive Type 1 cells were detected in normal cerebellum (arrowheads), 
whereas granule cells and Purkinje cells (P) were FABP7 negative. F, FABP7 and GFAP staining identified two distinctive popu-
lations of astrocytes. Arrowheads indicate the process of a FABP7-positive Type 1 cell. G, the number of FABP7-positive cells 
was increased in gliotic tissues, and Types 3 (arrow in inset) and 4 (arrowhead) cells appeared. H, in a region of perivascular 
gliosis, several GFAP+/FABP+ reactive astrocytes (Type 4) were seen. There were also FABP7-negative reactive astrocytes 
(arrowheads) and Type 1 cells (arrows) in this region. Strong immunofluorescence inside the vessel (V) was autofluorescence. 
I is a schematic summary of the morphology of the four types of glial cells identified in normal and gliotic adult brains. Gray 
color indicates FABP7 immunoreactivity. Note that Type 3 cells have gemistocytic characteristics and usually do not have 
nuclear FABP7. Bars in A,C,E,G, 50µm; bars in B, D, F, H, 20µm, and red and green fluorescence represents FABP7 and GFAP, 
respectively.BMC Cancer 2006, 6:97 http://www.biomedcentral.com/1471-2407/6/97
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cells were plated into each insert. After 4 hours, un-
migrated cells were removed with cotton swabs and
migrated cells were fixed and stained using a HEMA 3
stain set (Fisher Diagnostics, Middletown, VA). For each
insert, cell numbers were counted from five randomly
chosen fields under 200× magnification.
Data analysis
All statistical analyses used SPSS for Windows (Release
11.5.0). The fluorescence intensity recorded using the
Openlab software (Improvision, Lexington, MA) and
migration data were analyzed using Student's t test. Corre-
lation of nuclear localization of FABP7 with patient sur-
vival was analyzed using the Cox proportional hazards
regression. Hazard ratios provide information about the
direction of an association (a numeral over 1 indicates an
increased risk with the positive variable, and a numeral
under 1 indicates a decreased risk) as well as the magni-
tude of the risk. To evaluate the relationship between
nuclear FABP7 and EGFR upon patient survival, new vari-
ables were used to divide patients into four groups based
on the immunoreactivity of nuclear FABP7 and EGFR of
their tumors: dual negative as "0", nuclear FABP7-nega-
tive/EGFR-positive as "1", nuclear FABP7-positive/EGFR-
negative as "2", and dual positive as "3". Bivariate correla-
tions were evaluated by the Spearman test. A p value <
0.05 was considered statistically significant for all tests.
Results
Differential glial fibrillary acidic protein immunoreactivity 
identifies four subsets of fatty acid-binding protein 7-
expressing cells in adult normal and gliotic brain tissues
We compared expression and subcellular localization of
FABP7 in adult normal and gliotic brain specimens using
immunohistochemistry. In normal cerebrum, there was
minimal FABP7 reactivity in the white matter (data not
shown), and only scattered, predominantly nuclear
FABP7 immunoreactivity in the cortex (Fig. 1A). Morpho-
logically, the positive cells appeared to be glial in origin
but were negative for GFAP. These cells had a thin rim of
cytoplasm with no processes or with much fewer proc-
esses than their GFAP-positive counterparts (Fig. 1B). For
purpose of comparison, we named this unique group of
cells Type 1 cells. A separate population of GFAP-positive
cells in the subpial layer was also found to be positive for
FABP7 (Fig. 1C and 1D). We designated these cells Type 2
cells; these were distinguishable from Type 1 cells by their
location, elaborate processes, GFAP immunoreactivity,
and FABP7 staining throughout their nucleus, cytoplasm,
and processes. The presence of Type 2 cells in the subpial
layer is consistent with a previous finding in which FABP7
mRNA was found in the glia limitans of adult mice [27].
Endothelial cells and neurons were negative for FABP7
expression (Fig. 1A, and additional data not shown). In
the cerebellum, only scattered FABP7-positive glial cells
were identified, mostly in region of the Purkinje cell layer
(Fig. 1E), which is also in agreement with a previous in situ
hybridization study in mice [27]. These positive cells were
very similar to the Type 1 cells we identified in cerebral
cortex (Fig. 1F).
The expression of FABP7 and the number of FABP7-posi-
tive cells were increased in the cortex of gliotic brain spec-
imens, although the subcellular localization of FABP7 was
variable (Fig. 1G). In addition to the Type 1 cells, two dis-
tinct types of FABP7-positive cells, designated as Type 3
and Type 4 cells, were identified in gliotic cerebral cortex,
and were probably reactive astrocytes. Type 3 cells showed
FABP7 immunoreactivity mainly in their gemistocytic
cytoplasm, while nuclear staining was absent (Fig. 1G,
inset). Type 4 cells featured hypertrophic cytoplasm and
elaborate processes, and their nucleus, cytoplasm, and
processes are strongly positive for FABP7 (Fig. 1G). Both
Type 3 and Type 4 cells expressed GFAP (Fig. 1H), and
were not found in normal cerebral cortex, but only a sub-
set of reactive astrocytes expressed FABP7 (Fig. 1H).
Another feature in gliotic brain specimens was that FABP7
was weakly positive in the cytoplasm of some neurons
(data not shown). Figure 1I summarizes the morphology
of the four types of FABP7-expressing glial cells described
above.
Nuclear fatty acid-binding protein 7 is detected in 
neoplastic astrocytes in infiltrative types of glioma but not 
in grade I pilocytic astrocytoma
Because FABP7 demonstrates increased expression and
variable subcellular localization in a subset of reactive
astrocytes but not in most oligodendrocytes, we deter-
mined whether FABP7 is universally expressed in different
grades of astrocytoma. For comparison, we also examined
specimens from oligoastrocytoma (OAC) and oligoden-
droglioma (ODG).
An immunoblot of extracts from two GBM specimens and
two oligodendroglial tumors showed detectable levels of
FABP7 protein (Fig. 2A). We found that 1 of 5 grade II
astrocytoma specimens and 3 of 5 grade III astrocytoma
specimens were positive for FABP7. Paralleling the results
obtained from GBM specimens [9], both nuclear and
cytoplasmic FABP7 immunoreactivity was found in these
tumors (Fig. 2B and 2C). FABP7-positive reactive astro-
cytes similar in morphology to the Types 3 and 4 cells
(data not shown) were observed occasionally. We also
examined 10 pilocytic astrocytoma specimens (grade I),
and, in agreement with previous gene expression profiling
of this type of tumor [28], 9 of our specimens were posi-
tive for FABP7. Interestingly, the FABP7 immunoreactivity
in these 9 cases was predominantly in the cytoplasm and
cell processes, not in the nuclei (Fig. 2D). The presence of
nuclear FABP7 immunoreactivity in grades II, III, and IVBMC Cancer 2006, 6:97 http://www.biomedcentral.com/1471-2407/6/97
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astrocytoma specimens was statistically significant when
compared to grade I pilocytic astrocytoma (Table 1).
Among 19 grade III ODG specimens examined, FABP7
immunoreactivity was seen mostly in cells that were mor-
phologically similar to Types 3 and 4 cells (Fig. 3A and
3B) and appeared to be reactive astrocytes. Neoplastic oli-
godendrocytes did not express FABP7. Similar to gliotic
brain tissue, only a fraction of reactive astrocytes marked
by GFAP staining expressed FABP7. FABP7 could also be
detected in the nuclei and cytoplasm of microgemisto-
cytes in some ODG specimens (Fig. 3C and 3D). Micro-
gemistocytes are a group of neoplastic cells with
eosinophilic cytoplasm and GFAP immunoreactivity that
are sometimes present in ODG; however, half of our spec-
imens (3 of 6) that contained GFAP-positive microgemis-
tocytes did not express appreciable amounts of FABP7
(Fig. 3E and 3F). We found both cytoplasmic and nuclear
FABP7 immunoreactivity present in 4 of 7 grade II (Fig.
3G) and 8 of 10 grade III OAC specimens (Fig. 3H), and
those FABP7-immunoreactive specimens were also posi-
tive for GFAP (data not shown).
Nuclear fatty acid-binding protein 7 in glioblastoma is 
associated with epidermal growth factor receptor 
overexpression
Increased immunoreactivity of nuclear FABP7 correlated
with poor prognosis of GBM, particularly in younger
patients [9], and we sought to identify the molecular
mechanism underlying this association by investigating
EGFR expression in this tumor type.
EGFR expression evaluated by immunohistochemistry
using a group of primary GBM specimens from 61
patients (Table 2) showed a trend toward a negative asso-
ciation with survival (p = 0.074), which was marginally
correlated only in younger patients (less than the median
age of 53 years; p = 0.037, hazard ratio = 1.819, 95% CI
1.036–3.195) but not in the old ones (p = 0.875), consist-
ent with the previous finding [7]. Since we noted a similar
trend for nuclear FABP7 staining in this same set of speci-
mens [9], it raised the possibility of a correlation between
EGFR expression and nuclear FABP7. Indeed, EGFR
expression correlated with nuclear FABP7 (p = 0.008) but
not with cytoplasmic FABP7 (p = 0.547) in this set of spec-
imens. This finding is consistent with a detailed examina-
tion of FABP7/EGFR dual-positive GBM specimens with
separate regions of nuclear and cytoplasmic FABP7 immu-
noreactivity. We found that if a cluster of tumor cells had
only cytoplasmic FABP7 immunoreactivity, the EGFR
staining was minimal (Fig. 4A and 4B). In contrast, when
neoplastic cells in another region of the same tumor had
nuclear FABP7 immunoreactivity, the EGFR immunoreac-
tivity was usually prominent (Fig. 4C and 4D). The signif-
icant association between nuclear FABP7 and EGFR
immunoreactivity seemed to be present only when the
entire population, not specific age group, was analyzed,
since the correlation was greatly reduced in both younger
(p = 0.048, N = 31) and older groups (p = 0.055, N = 27)
divided by the median age (53 years) of the cases.
The link between EGFR and nuclear FABP7 appeared to be
specific for the neoplastic cells in GBM since nuclear
FABP7 immunoreactivity did not co-exist with EGFR
FABP7 was detected in all grades of astrocytomas Figure 2
FABP7 was detected in all grades of astrocytomas. A, lower, 
expression of FABP7 was analyzed Western blotting using 
lysate from normal white matter, two GBM specimens (H 
and L indicate high and low, respectively (high and low 
FABP7 expression based on the results of the previous 
microarray study [9]), one oligoastrocytoma grade III 
(OACIII), and one oligodendroglioma grade III (ODGIII); 
upper, the protein loading was demonstrated by Coomassie 
Blue staining. The arrow indicates the size of the FABP7 core 
protein. The 14 kD band in GBM (L) appeared after longer 
exposure of the film. The 18 kD band that appeared in the 
ODGIII lysate may not be non-specific, since several immu-
noreactive bands in that region could also be detected in 
lysate from a panel of glioma cell lines (data not shown). Rep-
resentative photomicrographs of immunohistochemistry of 
FABP7 in grade II astrocytoma (B), grade III anaplastic astro-
cytoma (C), and grade I pilocytic astrocytoma (D) demon-
strated distinctive FABP7 immunoreactivity in the cytoplasm 
and cell processes in pilocytic astrocytomas as opposed to 
the nuclear and cytoplasmic staining in grades II and III astro-
cytomas. FABP7-positive nuclei that were occasionally 
detected resembled the Type 1 cells seen in normal brain. 
The scale of the photomicrographs is the same as in Figure 1 
A.BMC Cancer 2006, 6:97 http://www.biomedcentral.com/1471-2407/6/97
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expression in several other types of specimens (data not
shown). These were: (1) FABP7-positive microgemisto-
cytes in ODG, (2) FABP7-positive reactive astrocytes in
morphologically normal brain regions surrounding the
EGFR-positive GBM, (3) FABP7-positive reactive astro-
cytes in gliotic tissues, and (4) Type 1 cells in normal cer-
ebrum. Likewise, EGFR-positive cells surrounding the
EGFR-overexpressing GBM that morphologically resem-
bled reactive astrocytes did not show FABP7 immunoreac-
tivity (data not shown).
We further examined whether the association between
nuclear FABP7 and EGFR expression is reflected on the
transcription level of both genes in two independent pub-
lished DNA microarray datasets (Table 3). Among the 34
GBM specimens analyzed by oligonucleotide microarrays
[29], mRNA expression of both FABP7 and EGFR genes
moderately correlated with each other (Fig. 5A, p =
0.016). In another report using 28 GBM specimens with
the same microarray system [30], expression of both genes
once again correlated with each other (Fig. 5B, p = 0.03).
This observation is in agreement with the marginal corre-
lation between EGFR and the combination of both
nuclear and cytoplasmic FABP7 immunoreactivity in our
61 specimens (p = 0.033).
The presence of nuclear FABP7 immunoreactivity in EGFR-
expressing GBM specimens is associated with shorter 
survival compared to those negative for nuclear FABP7
In our 61 GBM specimens poor survival was associated
with increased nuclear FABP7 immunoreactivity as well as
EGFR expression. Our data also showed that expression of
FABP7 gene and nuclear FABP7 immunoreactivity corre-
lated with mRNA and protein expressed by EGFR, respec-
tively. Therefore, we hypothesized that nuclear FABP7 and
EGFR expression might have additive association with
poor prognosis.
We examined the association of nuclear FABP7 with
patient survival in relation to the EGFR expression in the
55 cases (Table 2) that had all parameters available using
newly designated variables as defined in Methods: dual
negative as "0", nuclear FABP7-negative/EGFR-positive as
"1", nuclear FABP7-positive/EGFR-negative as "2", and
dual positive as "3". Cox regression analysis of these cases
(category 1 had only 4 cases and thereby was excluded)
showed that, although nuclear FABP7-positive tumors
(combining categories 2 and 3) demonstrated negative
association with survival (p = 0.022, hazard ratio = 1.408,
95% CI 1.05–1.888), the survival curves between speci-
mens of the categories 2 and 3 were indistinguishable
(Figure 6A, p = 0.509). However, we could not determine
the interaction between EGFR expression and nuclear
FABP7 immunoreactivity in the survival of GBM patients
since there were no enough cases from category 1.
We analyzed another group of 44 GBM specimens used in
our earlier study [9] that had more category 1 specimens
(N = 12, Table 4). Consistent with what was observed in
the previous set, cases from categories 2 and 3 together
had significantly shorter survival compared to those of
category 0 (p = 0.001, hazard ratio = 5.604, 95% CI
1.985–15.821), but showed no difference from each other
(Figure 6B, p = 0.692). Cox regression analysis showed
that the category 1 cases had shorter survival than
immuno-negative tumors but better prognosis compared
to the category 3 specimens (p = 0.009, hazard ratio =
4.167, 95% CI 1.421–12.222), suggesting that detection
of nuclear FABP7 immunoreactivity might predict poor
prognosis for EGFR-positive GBM.
Table 1: Summary of subcellular localization of fatty acid binding protein 7 in gliomas
Diagnosis Total Number 
examined
nuclear only or 
nuclear/cytoplasmic 
positive
Cytoplasmic positive 
only
negative p value1
grade I pilocytic 
astrocytoma
1 0 091 N A 2
g r a d e  I I  a s t r o c y t o m a 5104 0 . 0 0 3
g r a d e  I I I  a s t r o c y t o m a 5302 0 . 0 0 1
g r a d e  I V  G B M 9333 0 . 0 2 2
grade II 
oligoastrocytoma
7223 0 . 0 2 7
grade III 
oligoastrocytoma
10 5 3 2 0.006
grade III 
oligodendroglioma
19 3 0 16 NA3
1 The significance of nuclear FABP7 between 9 FABP7-positive grade I pilocytic astrocytoma specimens and the other type of FABP7-positive 
tumors was evaluated using Mann-Whitney test.
2 Minimal number of FABP7-positive nuclei were occasionally seen in all grade I tumors and we did not consider them for statistics.
3 FABP7 was not expressed in neoplastic oligodendrocytes.BMC Cancer 2006, 6:97 http://www.biomedcentral.com/1471-2407/6/97
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Table 2: A set of 61 GBM specimens for analyses of patient survival and the correlation between FABP7 and EGFR expression
Case # Diagnosis Age Survival 
(wk)
Censor FABP7 Nu FABP7 
Cyto
New 
Category*
EGFR IHC P53 IHC MIB-1
1 6 0 G B M 2 9 2 5 3 100000 1 6 . 3
3 8 1 G B M 3 2 2 2 0 100003 3 2 . 6
2 5 9 G B M 3 5 4 1 2 102003 5 . 9
4 9 5 G B M 3 8 1 2 5 102003 2 . 2
2 6 2 G B M 3 9 7 5 . 5 7 1 101003 1 2 . 7
3 2 2 G B M 4 0 3 3 . 5 7 1 100003 1 4 . 7
483 GBM 41 18.4286 1 0 1 0 0 1 6.2
4 9 9 G B M 4 3 2 6 . 1 4 3 100121 1 0 . 8
1 9 8 G B M 4 3 8 3 101003 3 2 . 7
3 1 0 G B M 4 3 6 6 . 1 4 3 102000 3 3 . 6
307 GBM 44 65.4286 1 0 1 0 0 3 29.1
497 GBM 44 138.429 1 0 1 0 0 0 62.1
436 GBM 45 151.286 1 0 0 0 0 1 6.6
212 GBM 46 106.571 1 0 0 0 0 2 39.6
2 0 8 G B M 4 9 6 8 . 4 2 9 101001 2 3 . 1
8 G B M 5 2 4 5 . 4 2 9 102111 5 . 9
501 GBM 53 115.571 1 0 0 0 0 3 47.5
330 GBM 53 20.7143 1 0 1 0 0 2 36.5
4 4 6 G B M 5 6 4 1 . 5 7 1 100003 3 9 . 2
4 0 4 G B M 5 6 6 8 . 8 5 7 102003 3 6 . 1
2 8 8 G B M 5 7 3 8 . 2 100112 2 1 . 8
1 9 G B M 5 8 8 0 . 4 2 9 102003 6 . 1
292 GBM 58 38.2 1 0 2 NA NA 0 NA
4 7 2 G B M 6 0 3 6 . 7 1 4 100000 5 2 . 6
2 8 6 G B M 6 1 5 1 . 2 8 6 102001 5 1 . 3
3 4 1 G B M 6 1 3 9 . 2 8 6 102003 7 5 . 2
1 3 5 G B M 6 3 2 1 . 1 4 3 102001 4 4 . 6
494 GBM 63 47.2 1 0 2 1 1 NA NA
4 2 6 G B M 6 4 8 3 . 1 4 3 102003 3 4 . 6
2 9 5 G B M 6 5 5 8 . 4 2 9 102003 2 2 . 1
260 GBM 67 22.5 1 0 0 NA NA 0 11.7
329 GBM 67 58.5 1 0 2 NA NA NA NA
3 2 1 G B M 6 9 2 4 . 5 7 1 100001 4 6 . 9
2 9 8 G B M 7 2 2 2 . 4 2 9 100001 2 7 . 5
3 0 9 G B M 7 6 2 9 . 4 2 9 100001 9 1 . 9
409 GBM 15 149.714 1 1 2 2 0 3 25.4
254 GBM 25 101.571 1 1 2 2 0 3 34.8
4 0 3 G B M 3 5 5 8 112201 3 7 . 9
1 9 2 G B M 5 1 3 6 111201 3 1 . 7
240 GBM 53 8.143 1 1 2 2 0 3 49.2
1 2 4 G B M 5 4 4 6 . 1 4 3 112201 4 1 . 7
470 GBM 56 81 1 1 2 NA NA 0 35.5
4 0 8 G B M 5 7 4 4 111201 3 2 . 8
4 2 5 G B M 5 7 1 5 . 1 4 3 111311 3 1 . 3
2 7 9 G B M 5 9 4 7 . 1 4 3 112312 2 3 . 4
493 GBM 68 49.5 1 1 2 NA NA NA NA
4 7 1 G B M 7 0 4 2 . 2 8 6 111320 2 5 . 5
4 9 6 G B M 7 0 5 5 . 8 5 7 111320 2 1 . 8
245 GBM 70 22.5 1 1 2 NA NA 2 22
2 4 1 G B M 3 2 3 3 . 1 4 3 120203 2 5 . 6
2 6 1 G B M 3 3 2 1 . 5 7 1 122202 5 0 . 1
297 GBM 43 107.571 1 2 2 3 1 2 32.9
3 2 3 G B M 4 6 8 1 122201 1 6 . 9
2 6 3 G B M 4 7 3 3 . 2 8 6 122323 1 7 . 8
9 0 G B M 4 8 6 6 . 8 5 7 121321 1 5 . 4
2 3 0 G B M 5 0 1 7 . 7 1 4 122201 3 5 . 8
227 GBM 52 53.1429 1 2 2 3 1 1 43.1
3 2 5 G B M 5 2 3 2 . 1 4 3 122320 2 0 . 3
4 4 3 G B M 5 5 5 9 . 2 8 6 121321 3 9 . 7BMC Cancer 2006, 6:97 http://www.biomedcentral.com/1471-2407/6/97
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Epidermal growth factor treatment increases  immunoreactivity of fatty acid-binding protein 7 in nucleus
To investigate whether EGFR activation-induced FABP7
expression observed in Schwann cells [13] is present in
GBM, we examined FABP7 expression and its subcellular
localization upon EGFR activation. Four commonly used
EGFR-expressing glioma cell lines, U87, U251, SF763, and
SF767, were examined for FABP7 expression using immu-
nohistochemistry, and all these lines demonstrated both
cytoplasmic and nuclear FABP7 immunoreactivity (data
not shown). The SF763 glioma cell line was chosen for
this study because it had the lowest ratio of nuclear to
cytoplasmic FABP7 as compared to other cell lines, and
induction of FABP7 nuclear translocation by EGFR activa-
tion could be easily detected. 
In SF763 cells, FABP7 expression increased after EGF treat-
ment (Fig. 7A and 7B). To avoid artifacts caused by the
heterogeneity of immunostaining or the increased expres-
sion of FABP7 after EGFR activation, the ratio of nuclear
to cytoplasmic FABP7 immunoreactivity of each cell was
calculated. The nuclear to cytoplasmic ratio of FABP7
staining in EGF-treated SF763 cells was statistically higher
than in the group without EGF treatment (p < 0.001, Fig.
7C), suggesting that nuclear translocation of FABP7 in
GBM could be induced by EGFR activation.
Epidermal growth factor-induced glioma cell migration is 
suppressed by inhibiting fatty acid binding protein 7 
expression
Since both EGFR activation [31] and forced expression of
FABP7 [9] promote glioma cell migration, we examined
whether inhibiting the expression of FABP7 can suppress
glioma cell migration induced by EGF.
Antisense oligodeoxynucleotides (ODNs) have been suc-
cessfully used to reduce expression of other members of
the FABP family [32], so we examined whether inhibiting
FABP7 expression with ODNs affects glioma cell migra-
tion. We found that FABP7-specific antisense ODNs sup-
pressed more than one-third of EGF-induced SF763 cell
migration, but had no effect on migration of the cells
without EGF treatment (Fig. 7D). This result strongly sug-
gests that at least a portion of EGF-induced glioma cell
migration is mediated through FABP7.
Discussion
In previous work, we identified nuclear FABP7 immuno-
reactivity as a prognostic marker for patients with GBM
FABP7 is expressed in GFAP-positive cells in ODG and OAC Figure 3
FABP7 is expressed in GFAP-positive cells in ODG and 
OAC. In grade III ODG, FABP7 (A) was expressed only in a 
subset of reactive astrocytes resembling Types 3 (arrow) and 
4 (arrowhead) cells when compared to numerous GFAP-
positive cells in an adjacent section (B). FABP7 was expressed 
in both nuclei and cytoplasm of the microgemistocytes (C) 
that were GFAP-immunoreactive (D). However, some 
tumors with microgemistocytes clearly did not express 
detectable amount of FABP7 (E) compared to GFAP (F). 
FABP7 was also seen in both nuclei and cytoplasm of tumor 
cells in some grades II (G) and III (H) OAC, and adjacent sec-
tions showed that the same groups of cells were GFAP posi-
tive (data not shown). The scale of the photomicrographs is 
the same as in Figure 1 A.
2 9 6 G B M 5 9 3 9 120201 4 4 . 9
3 3 5 G B M 7 5 1 8 . 1 4 3 122201 2 7 . 5
*Based on nuclear FABP7 and EGFR immunoreactivity: dual negative as "0", nuclear FABP7-/EGFR+ as "1", nuclear FABP7+/EGFR- as "2", and dual 
positive as "3"
NA, no IHC data available.
Table 2: A set of 61 GBM specimens for analyses of patient survival and the correlation between FABP7 and EGFR expression BMC Cancer 2006, 6:97 http://www.biomedcentral.com/1471-2407/6/97
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[9]. In a separate report, increased expression of FABP7
was also found in GBM patients surviving less than 2 years
compared to those who survived longer [29]. Two cellular
functions for FABP7 have been identified: cell migration
and differentiation in the developing central nervous sys-
tem [11], and Schwann cell-axonal interactions in the
peripheral nervous system [13]. Although suggestive, nei-
ther offers a clear explanation of the action of FABP7 in
gliomas. The goals of this study were to determine a plau-
sible biological role for FABP7 in glioma pathogenesis.
We characterize the expression of FABP7 in normal brain,
gliotic tissues, and glial tumors. We show that increased
FABP7 expression occurs in a subset of reactive astrocytes,
that FABP7 expression is restricted to cells of astrocytic lin-
eage in glioma, and that there is almost no nuclear FABP7
immunoreactivity in well-circumscribed pilocytic astrocy-
toma. In addition, we establish an association between
nuclear FABP7 and EGFR expression both in human GBM
tumors and in a glioma cell line. Our data suggest that
FABP7 might play a role in GBM pathogenesis through its
participation in the EGFR signaling pathways. Most
importantly, we identify nuclear FABP7 immunoreactivity
as a marker to predict the outcome of patients with EGFR-
positive GBM.
Transcription of both FABP7  and  EGFR  genes showed
marginal association based upon the microarray datasets,
but only nuclear FABP7 immunoreactivity correlated with
EGFR expression. Age is one of the most important prog-
nostic factors for GBM patients, and it has been shown in
separate studies that the status of EGFR expression is a bet-
ter prognostic factor in younger patients [7,33]. Our data
indicate that the prognostic value of nuclear FABP7 is also
influenced by patient age [9]. However, the correlation
between nuclear FABP7 and EGFR expression did not
have preference to patient age in our study. Collectively, it
appears that other factors (age is probably one of them,
see below) yet to be identified participate in regulating the
transcriptional and translational mechanisms shared by
both FABP7 and EGFR genes, as well as in regulating the
subcellular localizations of FABP7. This is compatible
with the fact that EGFR expression and nuclear FABP7
immunoreactivity are mutually exclusive in a significant
portion our clinical specimens. It will be pressing to
define in the future why nuclear FABP7 is not present in
some EGFR-positive GBM and whether other EGFR-
Scattered plot analyses of the expression levels of FABP7 and  EGFR genes Figure 5
Scattered plot analyses of the expression levels of FABP7 and 
EGFR genes. The abundance of mRNA for both genes 
obtained by microarrays was presented on a log2 base. A 
strong positive correlation of FABP7 and EGFR expression 
was seen in a set of 34 GBM specimens (A, p = 0.016), which 
was validated by a public microarray dataset using 28 GBM 
specimens (B, p = 0.03).
EGFR expression is associated with nuclear but not cytoplas- mic FABP7 immunoreactivity Figure 4
EGFR expression is associated with nuclear but not cytoplas-
mic FABP7 immunoreactivity. In one region of a representa-
tive GBM specimen, the cytoplasm of neoplastic 
gemistocytes had pronounced FABP7 immunoreactivity but 
the nuclei of the same cells were negative (A). In an adjacent 
section of the same specimen only minimal EGFR staining 
was seen in the same population of tumor cells (B). In 
another region of the same specimen, all nuclei of neoplastic 
astrocytes were marked by FABP7 staining (C), and EGFR 
expression was also prominent in these cells (D). The scale of 
photomicrographs is the same as in Figure 1 A.BMC Cancer 2006, 6:97 http://www.biomedcentral.com/1471-2407/6/97
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downstream pathways are active in EGFR-negative/
nuclear FABP7-positive tumors.
It has been previously reported that EGFR signaling
induces FABP7 expression in a Ras-independent pathway
in normal and tumor Schwann cells [13], providing evi-
dence of possible interaction between these two proteins.
Our demonstration in GBM specimens that expression of
both FABP7 and EGFR correlated with each other at both
protein and mRNA levels, and in SF763 glioma cells that
EGFR activation induced nuclear translocation of FABP7,
warrants further investigation of whether FABP7 is a direct
downstream target of EGFR activation in GBM and which
EGFR pathway FABP7 is associated with. It has been
EGF activation induces nuclear translocation of FABP7 in gli- oma cells Figure 7
EGF activation induces nuclear translocation of FABP7 in gli-
oma cells. Immunofluorescent staining of FABP7 in SF763 gli-
oma cells displayed both cytoplasmic and nuclear 
immunoreactivity (A), whereas FABP7 staining in the nuclei 
was increased after EGF treatment for 2 days (B). The scale 
of photomicrographs is the same as in Figure 1A. C, the sum 
of nuclear and cytoplasmic FABP7   fluorescence in SF763 
cells in each of the 10 randomly chosen fields was   calcu-
lated, and EGF treatment significantly increased total FABP7   
fluorescence. D, the ratios of nuclear/cytoplasmic FABP7 in 
untreated SF763   glioma cells and cells treated with 50 ng/ml 
of EGF for 1 day were   semi-quantitatively measured. For 
each group, ratios of 20 cells were   calculated from each of 
the 10 randomly chosen fields (p < 0.001). E,   control SF763 
cells demonstrated no difference in migration in the presence   
of either FABP7-specific sense or antisense ODNs (*, p = 
0.136), whereas   migration of EGF-treated SF763 cells was 
reduced by more than one-third in   the presence of anti-
sense ODNs (**, p = 0.004). F, FABP7 polyclonal   antibodies 
also inhibited migration of both control and EGF-treated 
SF763   cells (*, p=0.003; **, p=0.01). Error bars represented 
the standard errors   of the mean.  
Kaplan-Meier analysis of the first set of 55 GBM patients  based on the new   categories (0, N = 28; 1, N = 4; 2, N = 13;  3, N=10) of nuclear FABP7 and   EGFR expression (see  Methods) showed that dual-negative specimens had   signifi- cant longer survival time (A) Figure 6
Kaplan-Meier analysis of the first set of 55 GBM patients 
based on the new   categories (0, N = 28; 1, N = 4; 2, N = 13; 
3, N=10) of nuclear FABP7 and   EGFR expression (see 
Methods) showed that dual-negative specimens had   signifi-
cant longer survival time (A). Kaplan-Meier analysis of an   
independent set of 44 younger GBM patients (0, N = 11; 1, N 
= 12; 2, N = 11;   3, N=10) showed gradual decrease of sur-
vival time based on increased   expression of nuclear FABP7 
and EGFR (B). Red, category 0; yellow, category   1; green, 
category 2; blue, category 3.BMC Cancer 2006, 6:97 http://www.biomedcentral.com/1471-2407/6/97
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shown that liver-type FABP carries fatty acids to interact
with nuclear receptors that in turn regulate gene expres-
sion [22-24]. If FABP7 utilizes a similar mechanism to reg-
ulate gene expression in response to EGFR activation, this
would expand the scope of EGFR signaling pathways in
GBM tumors. Future studies will examine the specific
molecular pathways linking EGFR and FABP7, and
nuclear functions of FABP7.
In normal cerebral cortex, we identify a unique popula-
tion of glia positive for FABP7 but negative for GFAP that
we designated as Type 1 cells. The origin and exact role of
these cells remains unclear. NG2, a chondroitin sulfate
proteoglycan, is expressed by oligodendrocyte progeni-
tors, and identification of one type of GFAP-negative/
NG2-positive astrocytes in adult normal brain and a sub-
set of gliomas led to a hypothesis that certain gliomas
arise from the NG2-positive progenitor cells [34]. Accord-
ing to the morphology and frequency of appearance [35],
Type 1 cells identified in this study clearly do not belong
to this category. However, based upon the expression pat-
terns of FABP7 during the development of central nervous
system, in adult brain, and in gliomas, transformation of
FABP7-positive cells may contribute to the histogenesis of
a subgroup of gliomas.
In gliotic brain tissue, FABP7 expression is increased in a
subset of reactive astrocytes and demonstrates variable
subcellular localization in the cytoplasm and nucleus.
Such differential patterns in both expression and subcel-
lular localization of FABP7 are also seen in cells with
astrocytic features in various types of glioma. As noted
above, grade I pilocytic astrocytoma is the only type of gli-
oma examined that does not show nuclear FABP7 staining
in our studies. Although our size of sampling was limited,
the statistical analyses clearly demonstrate that the chance
of detecting nuclear FABP7 in pilocytic astrocytoma is
small. Because pilocytic astrocytomas are well-demarcated
lesions whose pattern of growth is clearly distinctive from
diffusely infiltrative higher-grade (grades II to IV) astrocy-
toma and oligodendroglial tumors (both ODG and
OAC), considering the association of nuclear FABP7 with
poor prognosis of GBM patients, cytoplasmic localization
of FABP7 may be associated with less infiltrative pheno-
type of neoplastic astrocytes. Interestingly, we did find
positive correlation between cytoplasmic FABP7 immu-
noreactivity and patient survival in cases older than the
medium age among the first set of 61 GBM specimens
(data not shown), although this observation has not been
validated in an independent set of samples. It would be
important in the future to investigate the downstream sig-
naling pathways for FABP7 in the nucleus and cytoplasm
and their association with cell motility, and how the trans-
location of FABP7 is regulated, especially under the con-
text of patient age.
Although FABP7 expression does not predict the outcome
of patients with ODG and OAC [36], FABP7 may have
prognostic value for grade II and grade III astrocytomas
due to its heterogeneous patterns of expression and sub-
cellular localization in these two tumor types. In other
experiments, we noted that immortalized non-tumori-
genic astrocytes express similar amounts of FABP7 com-
pared to glioma cell lines (data not shown). FABP7
overexpression in glioma cells does not affect cell cycle
progression and activation of apoptosis [9]. In gliotic
brain tissue increased FABP7 expression coincides with
GFAP expression in a subset of reactive astrocytes.
Increased expression of FABP7 was seen in brain tissues
after systematic administration of a neurotoxin, kainic
acid [14]. FABP7 was released into patients' serum after
acute ischemic stroke [37]. For these reasons, FABP7
expression or the presence of nuclear FABP7 alone is
unlikely a factor unique to glioma oncogenesis and pro-
gression. On a practical level, however, anecdotal experi-
ence suggests that occasional cases exist where the main
differential diagnosis is pilocytic astrocytoma versus GBM
(both of these astrocytic tumors exhibit microvascular
proliferation), and the presence of nuclear FABP7  would-
support the diagnosis of GBM.
In addition to this report, elevated levels of FABP7 mRNA
and protein in GBM specimens compared to those in nor-
mal adult brain have been previously demonstrated
[9,12]. Opposite results were reported in breast and pros-
tate cancer, where decreased expression of FABP7 was
found in tumor specimens when compared to normal tis-
sues [19,32]. Greater FABP7 expression was seen in rarely
metastasized melanoma cell lines compared to their fre-
quently metastasizing counterparts [38]. Poorly-differen-
tiated prostate tumors lose FABP7 expression, but more
FABP7 is expressed in well-differentiated prostate cancer
specimens than in primary normal prostate cells [32].
Ectopic expression of FABP7 induces cell differentiation
and suppresses tumor growth [19,20] and was shown to
mediate the cytotoxicity of DHA to breast cancer cells
[20]. One explanation for these divergent results in pat-
terns of expression and effects of forced expression is that
functions of FABP7 in neoplastic and normal cells are tis-
sue-specific. A strong candidate factor involved in such tis-
sue-specific functions is EGFR, since we observed in
clinical specimens the correlation of gene expression
between FABP7 and EGFR, and the correlation of nuclear
FABP7 immunoreactivity with EGFR expression; however,
this association appears to be only in GBM, but not in
normal brain, gliotic tissues, or other types of glioma
examined.
Our immunohistochemical results show the change of
subcellular localization of FABP7 in normal, gliotic, and
neoplastic brain tissues and suggest several interestingBMC Cancer 2006, 6:97 http://www.biomedcentral.com/1471-2407/6/97
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avenues for future studies. Based on its amino acid
sequence and protein structure, the primary activity of
FABP7 appears to be binding of fatty acids. Although the
binding affinity of FABP7 for various types of long-chain
fatty acids has been studied in vitro, and a likely in vivo lig-
and for FABP7 has been proposed [15], the actual fatty
acids bound to FABP7 are yet to be determined. Because
FABP7 does not possess an obvious nuclear localization
signal, nuclear translocation of FABP7 might require other
carrier proteins. Defining these interacting proteins and
ligands should clarify the biological roles of FABP7.
Conclusion
FABP7 is preferentially expressed in cells of astrocytic fea-
tures, and demonstrates variable expression levels and
subcellular localization in gliotic tissues and all grades of
astrocytoma, indicating that FABP7 expression alone does
not contribute to malignant progression of astrocytomas.
However, nuclear localization of FABP7 may be associ-
ated with infiltrative phenotype of glioma cells and EGFR
pathways based on several findings: correlation of nuclear
FABP7 immunoreactivity with poor prognosis of younger
patients with GBM, association with EGFR expression in
GBM, lack of nuclear FABP7 immunoreactivity in grade I
astrocytomas, and induction of translocation of FABP7
into nucleus in glioma cells after EGFR activation.
Abbreviations
FABP7, brain-type fatty acid-binding protein; GBM, gliob-
lastoma; EGFR, epidermal growth factor receptor; DHA,
docosahexaenoic acid; GFAP, glial fibrillary acidic pro-
tein; ODN, oligodeoxynucleotide; CI, confidence interval.
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Table 3: Expression of FABP7 and EGFR mRNA in GBM from two independent published DNA microarray datasets
Dataset 1 (ref. 29) Dataset 2(ref. 30)
Case # FABP7 EGFR Case # FABP7 EGFR
47.0 227.5 763.5 1375 28.8 233.8
210.4 337.0 1113.8 276 1010.0 775.2
193.0 555.6 831.6 519 72.1 46.7
21.7 974.6 471.4 368 418.2 14.7
97.3 1277.9 146.0 157 6.3 35.2
147.9 1384.4 188.3 1162 378.0 139.9
365.0 1758.1 625.4 1644 9.8 165.8
131.7 1908.4 367.4 406 950.8 341.8
459.4 2126.0 1522.5 308 611.3 473.7
33.9 2246.2 2588.0 177 817.8 630.8
58.7 2250.7 558.9 103 313.2 74.4
158.0 2289.3 327.5 992 1024.3 842.2
22.3 2351.9 224.2 41 952.3 56.6
97.9 2480.0 578.6 1354 101.3 182.9
14.0 2662.4 1134.1 308 424.0 169.2
205.9 2746.3 357.6 408 279.7 97.3
232.0 3071.7 220.9 242 1137.2 673.9
226.6 3190.2 547.5 323 218.8 208.4
29.4 3944.2 196.8 213 219.6 49.0
68.0 4158.9 3010.9 97 352.8 87.4
5.3 4496.3 625.6 281 978.6 357.0
31.1 4831.9 7883.7 501 1166.7 64.5
83.0 5120.5 1440.0 670 461.1 444.7
80.0 5508.2 2871.1 729 1711.5 8.9
82.0 5854.7 741.7 21 1690.3 2057.1
103.6 6008.9 9373.4 630 353.7 274.0
2.6 6850.0 3259.5 263 460.3 375.6
41.3 7593.1 441.2 219 486.4 179.7
60.9 7966.5 7258.6
46.1 8795.5 284.8
40.3 8946.3 410.0
58.3 11070.1 3518.5
50.4 11956.1 10788.3
16.3 13108.3 6798.5BMC Cancer 2006, 6:97 http://www.biomedcentral.com/1471-2407/6/97
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Table 4: An independent set of 44 GBM specimens to examine the effects of nuclear FABP7 and EGFR expression on patient survival
Case # Diagnosis Age Survival (wk) Censor FABP7 Nu EGFR IHC New Category*
17 GBM 54.2 73.2 1 0 0 0
30 GBM 24.3 203.9 1 0 0 0
45 GBM 45.2 67.9 1 0 0 0
46 GBM 26.9 146.7 0 0 0 0
66 GBM 17.5 133.5 0 0 0 0
68 GBM 31.6 146.9 1 0 0 0
81 GBM 51.1 60.6 1 0 0 0
84 GBM 43.6 66.8 0 0 0 0
87 GBM 59.9 43.4 1 0 0 0
91 GBM 46.4 383.0 0 0 0 0
94 GBM 54.0 33.7 1 0 0 0
98 GBM 39.1 48.6 1 0 1 1
99 GBM 56.9 128.1 1 0 1 1
107 GBM 59.1 79.8 1 0 2 1
110 GBM 45.2 35.1 1 0 2 1
148 GBM 59.8 35.1 1 0 2 1
194 GBM 54.8 32.7 1 0 2 1
225 GBM 54.1 94.3 1 0 2 1
243 GBM 50.6 76.8 1 0 2 1
263 GBM 54.7 123.1 1 0 2 1
277 GBM 42.5 25.1 0 0 2 1
284 GBM 47.7 92.3 1 0 2 1
29 GBM 35.3 97.0 1 0 2 1
89 GBM 55.2 45.1 1 1 0 2
273 GBM 42.5 39.0 0 1 0 2
4 GBM 51.0 29.5 1 1 0 2
21 GBM 59.3 32.7 1 1 0 2
32 GBM 58.2 22.1 1 1 0 2
53 GBM 51.2 23.8 1 2 0 2
54 GBM 33.1 32.7 0 2 0 2
58 GBM 37.2 31.1 1 2 0 2
61 GBM 12.8 12.3 0 2 0 2
88 GBM 52.2 93.9 1 2 0 2
100 GBM 45.8 11.3 1 2 0 2
103 GBM 55.1 13.9 1 2 2 3
105 GBM 41.7 46.1 1 2 2 3
106 GBM 43.8 10.5 0 2 2 3
207 GBM 51.3 27.1 1 2 2 3
240 GBM 45.2 13.3 1 2 2 3
247 GBM 58.7 43.3 1 2 2 3
265 GBM 58.8 80.1 1 2 2 3
34 GBM 54.4 36.0 1 1 1 3
38 GBM 23.0 24.1 1 1 2 3
50 GBM 25.0 41.0 1 1 2 3
*Based on nuclear FABP7 and EGFR immunoreactivity: dual negative as "0", nuclear FABP7-/EGFR+ as "1", nuclear FABP7+/EGFR- as "2", and dual 
positive as "3"BMC Cancer 2006, 6:97 http://www.biomedcentral.com/1471-2407/6/97
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